专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明授权

US07728115B2 Compositions and methods useful for the diagnosis and treatment of heparin induced thrombocytopenia/thrombosis 有权
标题翻译：用于肝素诱导的血小板减少/血栓形成的诊断和治疗的组合物和方法
公开(公告)号：US07728115B2
公开(公告)日：2010-06-01
申请号：US11195095
申请日：2005-08-02
申请人： Gowthami M. Arepally , Walter Kisiel , Keiko Kamei , Shintaro Kamei
发明人： Gowthami M. Arepally , Walter Kisiel , Keiko Kamei , Shintaro Kamei
IPC分类号： C07K16/18 , C12P21/08 , G01N33/564 , G01N33/577 , C12N5/20
CPC分类号： C07K16/24 , C07K16/18 , C07K2317/32 , C07K2317/75 , G01N33/86 , G01N2333/96463 , G01N2400/40 , Y10S435/975 , Y10S530/866
摘要： The invention includes compositions, kits and methods comprising a monoclonal antibody which shares key functional properties with the polyclonal antibodies which participate in the pathogenesis of heparin induced thrombocytopenia/thrombosis (HIT/HITT) in a mammal. The monoclonal antibody of the invention preferentially binds with a PF4/heparin complex relative to the binding of the antibody with PF4 or heparin alone. The monoclonal antibody of the invention also binds specifically with PF4 in a complex with other glycosaminoglycans besides heparin, and also activates platelets. The monoclonal antibody of the invention is useful in methods for diagnosing and treating HIT/HITT in a mammal. A humanized version of the monoclonal antibody of the invention is also included, along with a process for humanizing the monoclonal antibody of the invention.
摘要翻译：本发明包括组合物，试剂盒和方法，其包含与哺乳动物参与肝素诱导的血小板减少症/血栓形成（HIT / HITT）发病机理的多克隆抗体共享关键功能特性的单克隆抗体。本发明的单克隆抗体相对于抗体与单独的PF4或肝素的结合优先与PF4 /肝素复合物结合。本发明的单克隆抗体也与除了肝素之外的其它糖胺聚糖的复合物中的PF4特异性结合，并且还激活血小板。本发明的单克隆抗体可用于哺乳动物诊断和治疗HIT / HITT的方法。还包括本发明的单克隆抗体的人源化版本，以及本发明的单克隆抗体的人源化方法。

62. 发明授权

US06495336B1 Oligopeptide derivatives for the electrochemical measurement of protease activity 有权
标题翻译：寡肽衍生物用于电化学测量蛋白酶活性
公开(公告)号：US06495336B1
公开(公告)日：2002-12-17
申请号：US09914259
申请日：2001-11-21
申请人： Christian Ludin , Peter Wikstroem , Lars G. Svendsen , Andreas Schulze
发明人： Christian Ludin , Peter Wikstroem , Lars G. Svendsen , Andreas Schulze
IPC分类号： C07K5083
CPC分类号： C07K5/0812 , C07K5/0806 , C07K5/1016 , C12Q1/37 , G01N33/86 , G01N2333/96463
摘要： The invention relates to oligopeptide derivatives whose C-terminal amino acid is arginine which is linked to the remainder of an electroactive aniline or aminoquinoline derivative by an amide bond. The oligopeptide derivatives are split by enzymes of the class of peptide hydrolases, especially proteinases and their inhibitors, of the coagulation system, the fibrinolytic system and the complement system. These oligopeptide derivatives serve as substrates for quantitatively determining such enzymes, especially thrombin, in complex sample liquids, especially capillary blood. This determination is carried out by measuring the increase in the water-soluble amperogenic aniline or aminoquinoline compound. The oligopeptide derivatives and their salts can be produced according to usual methods in peptide chemistry.
摘要翻译：本发明涉及其C-末端氨基酸是通过酰胺键与电活性苯胺或氨基喹啉衍生物的其余部分连接的精氨酸的寡肽衍生物。寡肽衍生物被肽水解酶类，特别是蛋白酶及其抑制剂，凝血系统，纤维蛋白溶解系统和补体系统的酶分裂。这些寡肽衍生物用作定量测定复杂样品液体，特别是毛细管血液中的这些酶，特别是凝血酶的底物。该测定是通过测量水溶性高产苯胺或氨基喹啉化合物的增加来进行的。寡肽衍生物及其盐可以根据肽化学中的常规方法制备。

63. 发明授权

US5856114A Immunologic detection of factor VA fragments in hemorrhagic and thrombotic clinical settings 失效
标题翻译：在出血性和血栓性临床环境中的因子VA片段的免疫检测
公开(公告)号：US5856114A
公开(公告)日：1999-01-05
申请号：US606549
申请日：1996-02-26
申请人： Kenneth G. Mann , Michael Kalafatis
发明人： Kenneth G. Mann , Michael Kalafatis
IPC分类号： G01N33/86 , C12Q1/56
CPC分类号： G01N33/86 , G01N2333/96463
摘要： The present invention is directed to immunochemical detection procedures, e.g., using both Western blotting and direct immunoassays, for fragments of Factor Va, which can thus be used; (a) in a predictive manner to evaluate the existence and/or extent of a thrombotic complication; (b) to monitor the efficacy of prophylaxis for a thrombotic condition; and (c) as a means to evaluate potential risk of hemorrhage during thrombolytic therapy.
摘要翻译：本发明涉及免疫化学检测程序，例如使用Western印迹和直接免疫测定两者，因此可以使用因子Va片段; （a）以预测方式评估血栓并发症的存在和/或程度; （b）监测预防血栓形成的疗效; 和（c）作为评估溶栓治疗期间出血潜在风险的手段。

64. 发明授权

US5766869A Factor V ratio blood test for susceptibility to thromboembolism 失效
标题翻译：因子V比例血栓栓塞易感性血液检查
公开(公告)号：US5766869A
公开(公告)日：1998-06-16
申请号：US757926
申请日：1996-11-27
申请人： Yale S. Arkel , Dehui Wayne Ku
发明人： Yale S. Arkel , Dehui Wayne Ku
IPC分类号： C12Q1/56 , C12Q1/37 , G01N33/53
CPC分类号： C12Q1/56 , G01N2333/96461 , G01N2333/96463 , Y10S435/975
摘要： The disclosed Factor V Ratio (FVR) screening blood assay (read as "factor five ratio") and kits for the conduct thereof, identify individuals that possess a specific genetic defect, known as the Factor V Leiden defect, or other genetic or acquired Factor V defect, that makes those individuals susceptible to venous thromboembolism. In this test the Factor V activity of a blood plasma sample exposed to activated Protein C (APC) is compared to the Factor V activity of a similar sample in the absence of APC, after both samples had been treated with an activating agent. The ratio between the Factor V activity level without APC and the Factor V activity level with APC, identifies individuals at risk of a thrombotic disorder due to a Factor V defect and differentiates between individuals with a heterozygous defect and individuals with a homozygous defect.
摘要翻译：披露的因子V比（FVR）筛选血液测定（读作“因子5比”）和用于其进行的试剂盒识别具有特定遗传缺陷的个体，称为因子V莱顿缺陷，或其他遗传或获得性因子 V缺陷，使得这些个体对静脉血栓栓塞敏感。在这项测试中，暴露于活化蛋白C（APC）的血浆样品的因子V活性与两种样品均用活化剂处理后，在不存在APC的情况下与相似样品的因子V活性进行比较。不考虑APC的因子V活性水平与APC之因子V活性水平之间的比例，鉴定了由于因子V缺陷导致的血栓形成障碍风险的个体，并且区分具有杂合缺陷的个体和具有纯合缺陷的个体。

65. 发明授权

US11644410B2 Systems and methods for sample use maximization 有权
公开(公告)号：US11644410B2
公开(公告)日：2023-05-09
申请号：US17135437
申请日：2020-12-28
申请人： Labrador Diagnostics LLC
发明人： Anthony J. Nugent , Daniel L. Young , Elizabeth A. Holmes , Michael Siegel , Ryan Wistort
IPC分类号： G01N21/51 , G01N21/03 , B04B5/04 , G01N21/00 , B01L3/02 , G01N33/543 , H04N23/60 , C12Q1/42 , C12Q1/48 , C12Q1/6809 , C12Q1/689 , G01N21/59 , G01N33/569 , G01N33/573 , G01N33/74 , G01N33/80 , G06T3/40 , G06T7/00 , C12Q1/52 , C12Q1/6806 , G01N1/40 , G01N33/53 , G01N33/82 , G01N33/92 , G01N35/10 , G16C20/20 , G01N35/00
CPC分类号： G01N21/0303 , B01L3/0275 , B04B5/0421 , C12Q1/42 , C12Q1/48 , C12Q1/52 , C12Q1/6806 , C12Q1/689 , C12Q1/6809 , G01N1/4077 , G01N21/00 , G01N21/51 , G01N21/59 , G01N33/5308 , G01N33/54326 , G01N33/54393 , G01N33/56972 , G01N33/56983 , G01N33/573 , G01N33/74 , G01N33/743 , G01N33/80 , G01N33/82 , G01N33/92 , G01N35/10 , G06T3/4084 , G06T7/0002 , G06T7/0012 , H04N23/64 , B01L2300/168 , C12Q2600/158 , G01N2001/4083 , G01N2035/00495 , G01N2035/1018 , G01N2333/575 , G01N2333/62 , G01N2333/91188 , G01N2333/96463 , G06T2207/30004 , G06T2207/30168 , G16C20/20
摘要： The present invention provides systems, devices, and methods for point-of-care and/or distributed testing services. The methods and devices of the invention are directed toward automatic detection of analytes in a bodily fluid. The components of the device can be modified to allow for more flexible and robust use with the disclosed methods for a variety of medical, laboratory, and other applications. The systems, devices, and methods of the present invention can allow for effective use of samples by improved sample preparation and analysis.

66. 发明授权

US09989532B2 Methods and compositions for detecting coagulation inhibitors 有权
公开(公告)号：US09989532B2
公开(公告)日：2018-06-05
申请号：US14906620
申请日：2014-07-24
申请人： The University of North Carolina at Chapel Hill
发明人： Dougald Monroe , Jen-Yea Chang
IPC分类号： G01N33/573 , G01N33/50 , G01N33/86 , A61K38/17 , A61K38/48 , A61K38/57
CPC分类号： G01N33/573 , A61K38/1722 , A61K38/4833 , A61K38/4846 , A61K38/57 , C12Y304/21005 , C12Y304/21006 , G01N33/502 , G01N33/86 , G01N2333/96444 , G01N2333/96463 , G01N2500/00
摘要： The present invention provides a method of identifying a coagulation inhibitor in a sample, comprising: a) contacting a first portion of the sample with a substrate and thrombin; b) contacting a second portion of the sample with a substrate and a2M-thrombin (thrombin caged in alpha-2-macroglobulin); c) contacting a third portion of the sample with a substrate and coagulation factor Xa; d) contacting a fourth portion of the sample with a substrate and a2M-Xa (factor Xa caged in alpha-2-macroglobulin); and e) assaying for cleavage of the substrate in (a), (b), (c) and (d) above, wherein cleavage of the substrate in (b) and (d) and no cleavage in (a) and (c) identifies heparin in the sample; cleavage of the substrate in (a), (b) and (d) and no cleavage in (c) identifies low molecular weight heparin in the sample; cleavage of the substrate in (a) and (b) and no cleavage in (c) and (d) identifies rivaroxaban in the sample, and cleavage of the substrate in (c) and (d) and no cleavage in (a) and (b) identifies dabigatran in the sample.

67. 发明授权

US09677993B2 Systems and methods for sample use maximization 有权
公开(公告)号：US09677993B2
公开(公告)日：2017-06-13
申请号：US14789967
申请日：2015-07-01
申请人： Theranos, Inc.
发明人： Anthony Nugent , Daniel Young , Elizabeth A. Holmes , Michael Siegel , Ryan Wistort
IPC分类号： G01N21/00 , G01N33/569 , B04B5/04 , G01N33/543 , G01N21/03 , G01N21/51 , C12Q1/42 , C12Q1/48 , C12Q1/68 , G01N21/59 , G01N33/573 , G01N33/74 , G01N33/80 , G06T3/40 , G06T7/00 , H04N5/232 , C12Q1/52 , G01N1/40 , G01N33/53 , G01N33/82 , G01N33/92 , G01N35/10 , B01L3/02 , G06F19/00 , G01N35/00
CPC分类号： G01N21/00 , B01L3/0275 , B01L2300/168 , B04B5/0421 , C12Q1/42 , C12Q1/48 , C12Q1/52 , C12Q1/6806 , C12Q1/6809 , C12Q1/689 , C12Q2600/158 , G01N1/4077 , G01N21/0303 , G01N21/51 , G01N21/59 , G01N33/5308 , G01N33/54326 , G01N33/54393 , G01N33/56972 , G01N33/56983 , G01N33/573 , G01N33/74 , G01N33/743 , G01N33/80 , G01N33/82 , G01N33/92 , G01N35/10 , G01N2001/4083 , G01N2035/00495 , G01N2333/575 , G01N2333/62 , G01N2333/91188 , G01N2333/96463 , G06F19/703 , G06T3/4084 , G06T7/0002 , G06T7/0012 , G06T2207/30004 , G06T2207/30168 , H04N5/23222
摘要： The present invention provides systems, devices, and methods for point-of-care and/or distributed testing services. The methods and devices of the invention are directed toward automatic detection of analytes in a bodily fluid. The components of the device can be modified to allow for more flexible and robust use with the disclosed methods for a variety of medical, laboratory, and other applications. The systems, devices, and methods of the present invention can allow for effective use of samples by improved sample preparation and analysis.

68. 发明申请

US20160006928A1 SYSTEMS AND METHODS FOR SAMPLE USE MAXIMIZATION 审中-公开
公开(公告)号：US20160006928A1
公开(公告)日：2016-01-07
申请号：US14831838
申请日：2015-08-20
申请人： Theranos, Inc.
发明人： Ian Gibbons , Anthony Nugent , Anthony Delacruz , Daniel Young , Elizabeth A. Holmes , Andrew Drake , Timothy Michael Kemp , Sunny Balwani , Chinmay Pangarkar
IPC分类号： H04N5/232 , G06T7/00
CPC分类号： G01N21/00 , B01L3/0275 , B01L2300/168 , B04B5/0421 , C12Q1/42 , C12Q1/48 , C12Q1/52 , C12Q1/6806 , C12Q1/6809 , C12Q1/689 , C12Q2600/158 , G01N1/4077 , G01N21/0303 , G01N21/51 , G01N21/59 , G01N33/5308 , G01N33/54326 , G01N33/54393 , G01N33/56972 , G01N33/56983 , G01N33/573 , G01N33/74 , G01N33/743 , G01N33/80 , G01N33/82 , G01N33/92 , G01N35/10 , G01N2001/4083 , G01N2035/00495 , G01N2035/1018 , G01N2333/575 , G01N2333/62 , G01N2333/91188 , G01N2333/96463 , G06T3/4084 , G06T7/0002 , G06T7/0012 , G06T2207/30004 , G06T2207/30168 , G16C20/20 , H04N5/23222
摘要： The present invention provides systems, devices, and methods for point-of-care and/or distributed testing services. The methods and devices of the invention are directed toward automatic detection of analytes in a bodily fluid. The components of the device can be modified to allow for more flexible and robust use with the disclosed methods for a variety of medical, laboratory, and other applications. The systems, devices, and methods of the present invention can allow for effective use of samples by improved sample preparation and analysis.

69. 发明申请

US20150226731A1 PROTEASE-BASED BIOSENSOR 有权
标题翻译：基于PROTEASE的生物传感器
公开(公告)号：US20150226731A1
公开(公告)日：2015-08-13
申请号：US14427982
申请日：2013-09-12
申请人： THE UNIVERSITY OF QUEENSLAND
发明人： Kirill Alexandrov , Viktor Stein , Matt Trau
IPC分类号： G01N33/542 , G01N33/573 , C12N9/50
CPC分类号： G01N33/542 , C07K16/3069 , C07K16/36 , C07K2317/22 , C07K2317/569 , C07K2319/21 , C07K2319/50 , C07K2319/70 , C12N9/503 , C12N9/506 , C12N15/62 , C12N2770/24022 , C12N2770/34022 , C12Q1/37 , G01N33/532 , G01N33/54366 , G01N33/573 , G01N2333/005 , G01N2333/18 , G01N2333/96463
摘要： A biosensor molecule comprises: a protease amino acid sequence; at least one sensor comprising at least one sensor amino acid sequence which is responsive to at least one target molecule; and an inhibitor of the protease activity of said protease amino acid sequence; wherein the biosensor is switchable from a protease active to a protease inactive state, or from a protease inactive to a protease active state when said sensor responds to said target molecule. The biosensor protease may be a protease of a virus such as a Potyvirus or a Flavivirus wherein the inhibitor is an autoinhibitory peptide derived from the virus. The biosensor may respond to the target molecule allosterically or may be cleaved by a target protease molecule.
摘要翻译：生物传感器分子包括：蛋白酶氨基酸序列; 至少一个传感器包括至少一个对至少一个靶分子有响应的传感器氨基酸序列; 和所述蛋白酶氨基酸序列的蛋白酶活性的抑制剂; 其中当所述传感器响应于所述靶分子时，所述生物传感器可从蛋白酶活性切换到蛋白酶非活性状态，或从无活性蛋白酶转变为蛋白酶活性状态。生物传感器蛋白酶可以是诸如Potyvirus或黄病毒病毒的病毒的蛋白酶，其中抑制剂是源自病毒的自身抑制肽。生物传感器可以变构反应靶分子，或者可以被靶蛋白酶分子切割。

70. 发明授权

US09096674B2 Antibodies for determining the prothrombin fragment F2/F1+2 in a homogeneous immunoassay 有权
标题翻译：用于在均相免疫测定中测定凝血酶原片段F2 / F1 + 2的抗体
公开(公告)号：US09096674B2
公开(公告)日：2015-08-04
申请号：US12566464
申请日：2009-09-24
申请人： Matthias Ehm , Bodo Fischer , Harald Althaus , Roland Barten
发明人： Matthias Ehm , Bodo Fischer , Harald Althaus , Roland Barten , Stefan Teigelkamp
IPC分类号： C07K16/36 , C07K16/42 , C12N5/20 , C12P21/08 , G01N33/563 , G01N33/573 , G01N33/86 , C12N9/74
CPC分类号： C07K16/36 , C07K16/42 , C07K2317/32 , C07K2319/00 , C12N9/6429 , C12Y304/21005 , G01N33/563 , G01N33/573 , G01N33/86 , G01N2333/96463
摘要： The present invention is in the area of coagulation analysis and relates to antibodies which bind specifically to an immune complex of prothrombin fragment F2/F1+2 and an F2/F1+2 neoepitope-specific antibody fragment, and to the preparation and the use thereof in methods for determining F2/F1+2.
摘要翻译：本发明涉及凝血分析领域，涉及特异性结合凝血酶原片段F2 / F1 + 2和F2 / F1 + 2新表皮特异性抗体片段的免疫复合物的抗体及其制备及应用在确定F2 / F1 + 2的方法中。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式